Verdonck L F, de Graan-Hentzen Y C, Dekker A W, Mudde G C, de Gast G C
Department of Haematology, University Hospital, Utrecht, The Netherlands.
Bone Marrow Transplant. 1987 Jun;2(1):73-8.
The effect of a deliberate transfusion policy for prevention of primary cytomegalovirus (CMV) infection, consisting of leukocyte-poor red blood cells from random donors and platelets from CMV-negative donors, was studied in 29 CMV-negative negative recipients of an allogeneic (from CMV-negative donors) or autologous bone marrow transplant. All transplant recipients remained CMV-negative with this approach. Such a policy depends on the availability of CMV-negative platelet donors. Siblings from CMV-negative marrow transplantation candidates appeared to be more often CMV-negative than siblings from CMV-positive transplantation candidates (77% versus 34%, p less than 0.001). Selection of CMV-negative blood bank donors for transfusion of blood products is also easy to perform. As a consequence, CMV-negative marrow transplant recipients have a good chance of receiving CMV-negative marrow transplants and blood products and primary CMV infection can thus be prevented by this transfusion policy.
在29名接受同种异体（来自巨细胞病毒阴性供者）或自体骨髓移植的巨细胞病毒阴性受者中，研究了一种旨在预防原发性巨细胞病毒（CMV）感染的输血策略的效果，该策略包括使用随机供者的少白细胞红细胞和巨细胞病毒阴性供者的血小板。采用这种方法，所有移植受者均保持巨细胞病毒阴性。这种策略依赖于巨细胞病毒阴性血小板供者的可获得性。巨细胞病毒阴性骨髓移植候选者的兄弟姐妹似乎比巨细胞病毒阳性移植候选者的兄弟姐妹更常为巨细胞病毒阴性（77%对34%，p<0.001）。选择巨细胞病毒阴性血库供者进行血液制品输血也很容易操作。因此，巨细胞病毒阴性骨髓移植受者有很大机会接受巨细胞病毒阴性骨髓移植和血液制品，从而通过这种输血策略预防原发性巨细胞病毒感染。
